Alimera sciences continues global geographic expansion with launch of iluvien in finland for both indications

Atlanta, feb. 18, 2021 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that iluvien is now available in finland for diabetic macular edema (dme) and non-infectious uveitis affecting the posterior segment (nipu), and will be marketed by alimera and distributed by nordic prime.
ALIM Ratings Summary
ALIM Quant Ranking